SCHEMBL4743518

SCHEMBL4743518

CCCCCC(=O)NC(C(=O)O)C(C)CC

nearest known ligand 0.58

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
FAAH O00519 4/20 0.58
MAPK1 P28482 2/20 0.58
MEN1 O00255 1/20 0.58
KMT2A Q03164 1/20 0.58
ALDH1A1 P00352 2/20 0.54
NOD1 Q9Y239 2/20 0.51
PLA2G2A P14555 1/20 0.51
PLA2G5 P39877 1/20 0.51
SMN1; SMN2 Q16637 2/20 0.49
PLA2G10 O15496 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.47
PLA2G2C Q5R387 1/20 0.47
DNM1 Q05193 1/20 0.47
SLC6A5 Q9Y345 2/20 0.47
ASAH1 Q13510 1/20 0.46
ACER2 Q5QJU3 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6136152 1.00 FAAH (0.58) FAAHMAPK1MEN1KMT2AALDH1A1
SCHEMBL15650090 0.98 FAAH (0.61) FAAHMAPK1MEN1KMT2AALDH1A1
SCHEMBL15649988 0.98 FAAH (0.61) FAAHMAPK1MEN1KMT2AALDH1A1
SCHEMBL17204047 0.98 FAAH (0.61) FAAHMAPK1MEN1KMT2AALDH1A1
SCHEMBL25418775 0.98 FAAH (0.61) FAAHMAPK1MEN1KMT2AALDH1A1
SCHEMBL25419002 0.98 FAAH (0.61) FAAHMAPK1MEN1KMT2AALDH1A1
SCHEMBL21142179 0.98 FAAH (0.61) FAAHMAPK1MEN1KMT2AALDH1A1
SCHEMBL21142181 0.98 FAAH (0.61) FAAHMAPK1MEN1KMT2AALDH1A1
SCHEMBL21142180 0.98 FAAH (0.61) FAAHMAPK1MEN1KMT2AALDH1A1
SCHEMBL12350020 0.98 FAAH (0.61) FAAHMAPK1MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0946499-B1 N-(ARYL/HETEROARYL/ALKYLACETYL) AMINO ACID AMIDES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS ELAN PHARM INC (US) 2005-06-01 EP claimed
EP-0473700-A1 AN ENZYME-CATALYZED PROCESS FOR PREPARING N-ACYL AMINO ACIDS AND N-ACYL AMINO ACID AMIDES NOVO NORDISK A/S (DK) 1992-03-11 EP claimed
WO-1990014429-A1 AN ENZYME-CATALYZED PROCESS FOR PREPARING N-ACYL AMINO ACIDS AND N-ACYL AMINO ACID AMIDES NOVO NORDISK A/S (DK) 1990-11-29 WO claimed
US-20250000948-A1 SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID ADOCIA (FR) 2025-01-02 US disclosed
EP-4299057-A1 SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID Adocia (FR) 2024-01-03 EP disclosed
WO-2023084118-A1 SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID ADOCIA (FR) 2023-05-19 WO disclosed
EP-4180060-A1 SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID Adocia (FR) 2023-05-17 EP disclosed
CN-109081789-A The positive positive hexanoyl fatty acid/amino acid of hexanoyl amino first cyclic amide base of amino, synthesis, activity and application 首都医科大学 2018-12-25 CN disclosed
US-9642842-B2 Opioid receptor ligands and methods of using and making same Trevana, Inc. (US) 2017-05-09 US disclosed
WO-2008101313-A1 PREPARATION OF AMINO ACID-FATTY ACID AMIDES MULTI FORMULATIONS LTD. (CA) 2008-08-28 WO disclosed
US-20080200704-A1 PREPARATION OF AMINO ACID-FATTY ACID AMIDES MULTI FORMULATIONS LTD. (CA) 2008-08-21 US disclosed
EP-0946499-B1 N-(ARYL/HETEROARYL/ALKYLACETYL) AMINO ACID AMIDES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS ELAN PHARM INC (US) 2005-06-01 EP disclosed
EP-0473700-A1 AN ENZYME-CATALYZED PROCESS FOR PREPARING N-ACYL AMINO ACIDS AND N-ACYL AMINO ACID AMIDES NOVO NORDISK A/S (DK) 1992-03-11 EP disclosed
WO-1990014429-A1 AN ENZYME-CATALYZED PROCESS FOR PREPARING N-ACYL AMINO ACIDS AND N-ACYL AMINO ACID AMIDES NOVO NORDISK A/S (DK) 1990-11-29 WO disclosed
US-4442090-A ACYLATED AMINO ACID KYOTO YAKUHIN KOGYO KABUSHIKI KAISHA (JP) 1984-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080200704-A1 PREPARATION OF AMINO ACID-FATTY ACID AMIDES FABP2, FABP4, FABP1 FAAH 34/4885MAPK1 4068/4885MEN1 4322/4885
US-20250000948-A1 SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID NPPA, BCAT1, ANPEP FAAH 858/4885MAPK1 1499/4885MEN1 2101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.